LUNG vs. GUTS, SKIN, CERS, OSUR, NVRO, TMCI, TCMD, ANIK, INO, and SGHT
Should you be buying Pulmonx stock or one of its competitors? The main competitors of Pulmonx include Fractyl Health (GUTS), Beauty Health (SKIN), Cerus (CERS), OraSure Technologies (OSUR), Nevro (NVRO), Treace Medical Concepts (TMCI), Tactile Systems Technology (TCMD), Anika Therapeutics (ANIK), Inovio Pharmaceuticals (INO), and Sight Sciences (SGHT). These companies are all part of the "surgical & medical instruments" industry.
Pulmonx (NASDAQ:LUNG) and Fractyl Health (NASDAQ:GUTS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, community ranking and valuation.
Pulmonx currently has a consensus price target of $16.33, indicating a potential upside of 105.97%. Fractyl Health has a consensus price target of $22.00, indicating a potential upside of 214.29%. Given Fractyl Health's stronger consensus rating and higher possible upside, analysts plainly believe Fractyl Health is more favorable than Pulmonx.
In the previous week, Pulmonx had 3 more articles in the media than Fractyl Health. MarketBeat recorded 8 mentions for Pulmonx and 5 mentions for Fractyl Health. Pulmonx's average media sentiment score of 1.14 beat Fractyl Health's score of 0.23 indicating that Pulmonx is being referred to more favorably in the media.
Pulmonx has higher revenue and earnings than Fractyl Health.
Fractyl Health has a net margin of 0.00% compared to Pulmonx's net margin of -80.46%. Fractyl Health's return on equity of 0.00% beat Pulmonx's return on equity.
91.0% of Pulmonx shares are owned by institutional investors. 5.7% of Pulmonx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Pulmonx received 27 more outperform votes than Fractyl Health when rated by MarketBeat users. However, 100.00% of users gave Fractyl Health an outperform vote while only 43.48% of users gave Pulmonx an outperform vote.
Summary
Pulmonx beats Fractyl Health on 8 of the 15 factors compared between the two stocks.
Get Pulmonx News Delivered to You Automatically
Sign up to receive the latest news and ratings for LUNG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LUNG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
